Literature DB >> 6143207

Epoprostenol and platelet deposition in atherosclerosis.

H Sinzinger, P Fitscha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6143207     DOI： 10.1016/s0140-6736(84)91363-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Nuclear medicine and atherosclerosis.

Authors:  H Sinzinger; I Virgolini
Journal:  Eur J Nucl Med       Date:  1990

2.  Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in man.

Authors:  H Sinzinger; F Rauscha; J O'Grady; P Fitscha
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  Beneficial effect of PGI2 on circulating endothelial cells.

Authors:  H Sinzinger; F Rauscha; P Fitscha; J Kaliman
Journal:  Basic Res Cardiol       Date:  1988 Nov-Dec       Impact factor: 17.165

4.  Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.

Authors:  H Sinzinger; P Fitscha; J Kaliman; K Silberbauer; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

5.  Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.

Authors:  H Sinzinger; J O'Grady; P Fitscha
Journal:  Postgrad Med J       Date:  1987-04       Impact factor: 2.401
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.